Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia
- 14 June 2006
- journal article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 25 (7) , 457-462
- https://doi.org/10.1007/s10096-006-0161-8
Abstract
The aim of this study was to evaluate the effect of prior pneumococcal vaccination on the clinical outcome of 554 consecutive hospitalized adults with community-acquired pneumococcal pneumonia from 1995 to 2004, 61 of whom had been vaccinated in the 5 years before admission. Outcome variables that were compared in vaccinated and unvaccinated adults included the occurrence of bacteremia, the time to resolution of pneumonia symptoms, the length of hospital stay, and mortality. Prior pneumococcal vaccination was associated with a lower risk of bacteremia (odds ratio 0.46, 95% CI 0.22–0.98). Compared with unvaccinated patients, vaccine recipients had better clinical outcomes, which included a faster resolution of pneumonia symptoms. The median length of hospital stay was shorter in vaccinated patients (8.0 vs. 9.0 days; p=0.032). Overall case-fatality rates did not differ significantly between groups (1.6% vs. 6.2%; p=0.233). In conclusion, prior pneumococcal vaccination appears to be associated with a lower risk of bacteremia, a faster time to resolution of symptoms, and a shorter hospital stay in adults with pneumococcal pneumonia. The findings presented here provide additional support to the current vaccine recommendations and should encourage healthcare providers to increase pneumococcal vaccine coverage among targeted adult populations.Keywords
This publication has 20 references indexed in Scilit:
- Effectiveness of Pneumococcal Vaccination for Elderly People in Catalonia, Spain: A Case-Control StudyClinical Infectious Diseases, 2005
- Vaccinations in pneumonia (VIP): pneumococcal and influenza vaccination patterns among patients hospitalized for pneumoniaPreventive Medicine, 2005
- Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and RaceAnnals of Internal Medicine, 2003
- Effectiveness of Pneumococcal Polysaccharide Vaccine in Older AdultsNew England Journal of Medicine, 2003
- Evaluation of the Immunochromatographic Binax NOW Assay for Detection ofStreptococcus pneumoniaeUrinary Antigen in a Prospective Study of Community‐Acquired Pneumonia in SpainClinical Infectious Diseases, 2003
- Early Switch and Early Discharge Strategies in Patients With Community-Acquired PneumoniaArchives of internal medicine (1960), 2001
- Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European CountriesClinical Infectious Diseases, 2000
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly peopleThe Lancet, 1998
- Missed opportunities for pneumococcal and influenza vaccination of Medicare pneumonia inpatients--12 western states, 1995.1997